Mark B. Skaletsky
Chief Executive Officer at Fenway Pharmaceuticals, Inc.
Profile
Mark B.
Skaletsky currently works at Fenway Pharmaceuticals, Inc., as Chairman & Chief Executive Officer from 2009, Biotechnology Innovation Organization, as Treasurer, and Bentley University, as Trustee.
Mr. Skaletsky also formerly worked at GelTex Pharmaceuticals, Inc., as President & Chief Executive Officer from 1993 to 2000, Enzytech, Inc., as Chairman & Chief Executive Officer from 1988 to 1993, Althexis Co., Inc., as Chairman & Chief Executive Officer from 2000 to 2001, Trine Pharmaceuticals, Inc., as Chairman & Chief Executive Officer in 2007, Domantis Ltd., as Chairman, Targacept, Inc., as Chairman from 2001 to 2013, Alkermes, Inc., as Lead Independent Director in 2011, ImmunoGen, Inc., as Independent Director from 2011 to 2013, Ionis Pharmaceuticals, Inc., as Director, Cogenics Icoria, Inc., as Director, ABIONYX Pharma SA, as Director, Kiadis Pharma BV, as Director-Supervisory Board, AMAG Pharmaceuticals, Inc., as Director from 2003 to 2009, Alkermes Plc, as Independent Director from 2012 to 2013, and Biogen MA, Inc., as President, Chief Operating & Financial Officer from 1981 to 1988.
Mr. Skaletsky received his undergraduate degree in 1970 from Bentley University.
Mark B. Skaletsky active positions
| Companies | Position | Start |
|---|---|---|
| Bentley University | Director/Board Member | - |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Director/Board Member | - |
Fenway Pharmaceuticals, Inc.
 Fenway Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Fenway Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It provides drug development services. The company is headquartered in Newton, MA | Chief Executive Officer | 2008-04-30 |
Former positions of Mark B. Skaletsky
| Companies | Position | End |
|---|---|---|
| IMMUNOGEN, INC. | Director/Board Member | 2013-11-11 |
Targacept, Inc.
 Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | Chairman | 2013-11-10 |
| ALKERMES PLC | Director/Board Member | 2013-11-10 |
Alkermes, Inc.
 Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Director/Board Member | 2011-09-15 |
| AMAG PHARMACEUTICALS, INC. | Director/Board Member | 2009-12-30 |
Training of Mark B. Skaletsky
| Bentley University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| IMMUNOGEN, INC. | Health Technology |
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| ABIONYX PHARMA | Health Technology |
| ALKERMES PLC | Health Technology |
| Private companies | 13 |
|---|---|
Alkermes, Inc.
Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Health Technology |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
GelTex Pharmaceuticals, Inc.
 GelTex Pharmaceuticals, Inc. BiotechnologyHealth Technology GelTex Pharmaceuticals, Inc. was developed non-absorbed, polymer-based pharmaceuticals that selectively bind and eliminate target substances from the intestinal tract. The company is a subsidiary of Geltex Corp. GelTex Pharmaceuticals was founded by Henry E Blair & James B Tananbaum in 1991 and was located in Waltham, MA. | Health Technology |
Cogenics Icoria, Inc.
 Cogenics Icoria, Inc. Miscellaneous Commercial ServicesCommercial Services Cogenics Icoria, Inc. provides medical research services. The firm offers genomics and proteomics-related research instruments, consumables, data, including databases, software & other research-oriented products. Icoria offers gene expression analysis and other related services. Its tissue informatics software performs tissue analysis for toxicology studies of early-stage drug candidates and other purposes. The firm also provides biomarkers to develop diagnostics and therapies for liver injuries, metabolic conditions & cancer. The company is headquartered in Research Triangle Park, NC. | Commercial Services |
Domantis Ltd.
 Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Fenway Pharmaceuticals, Inc.
Fenway Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Fenway Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It provides drug development services. The company is headquartered in Newton, MA | Health Technology |
Enzytech, Inc.
 Enzytech, Inc. Pharmaceuticals: MajorHealth Technology Enzytech, a biopharmaceutical company founded in 1987, developed mechanisms to deliver smaller doses of drugs specifically to their targets. | Health Technology |
Althexis Co., Inc.
 Althexis Co., Inc. Miscellaneous Commercial ServicesCommercial Services Althexis Co., Inc. researches and develops drugs for the treatment of human diseases. The company is based in Waltham, MA. Mass. The company was founded by Manuel A. Navia, Paul J. Althexis Co. was acquired by Essential Therapeutics, Inc. on October 25, 2001 for $18.84 million. | Commercial Services |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | Health Technology |
Trine Pharmaceuticals, Inc.
 Trine Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Trine Pharmaceuticals, Inc. develops and markets pharmaceutical products. It develops drugs which are used in the areas of renal, gastrointestinal and metabolic diseases. The company is headquartered in Waltham, MA. | Health Technology |
Kiadis Pharma BV
 Kiadis Pharma BV Pharmaceuticals: MajorHealth Technology Kiadis Pharma BV operates as a is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Its products include: ATIR101 and ATIR201. The firm’s products are based on hematopoietic blood-forming stem cell transplants from donors. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
- Stock Market
- Insiders
- Mark B. Skaletsky
